CompletedNot Applicable

B-Receptor Signaling in Cardiomyopathy

United States99 participantsStarted 2008-11

Plain-language summary

We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.) Echocardiogram at least six months after exposure to anthracyclines (in patients over the age of 40, the echocardiogram must be obtained within 6 - 48 months of anthracycline exposure)
✓.) Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

✕.) Pre-existing cardiomyopathy before anthracycline administration
✕.) Patients with Down syndrome
✕.) Patients receiving B-blocker therapy at the time of anthracycline exposure
✕.) Pregnant patients (if their echocardiogram was obtained either during pregnancy or within three months of pregnancy)

What they're measuring

Development of cardiomyopathy

Timeframe: Within 5 years after receiving anthracyclines.

Trial details

NCT IDNCT01135849

SponsorDaniel Bernstein

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2010-10

View on ClinicalTrials.gov More Carcinomas trials